Morgan Stanley downgrades AIG to Underweight from Equal Weight...
Merrill Lynch out with a note calling biotech's underperformance vs the Nasdaq in H2:2003 a buying opportunity; firm continues to recommend AMGN, DNA, GILD and MEDI is large cap and OSIP, MOGN, NPSP in the small cap arena...
UBS upgrading TXN to Buy from Neutral, while downgrading DUK, VC and ACI...
JP Morgan ups DV to Overweight and adds to U.S. Focus List, while cutting EW to Underweight from Neutral...
Piper Jaffray upgrading JDAS to Outperform from Mkt Perform and SLAB to Mkt Perform from Underperform...
First Albany upgrading NEOL to Buy from Neutral, raising tgt to $23 from $14, while downgrading JCOM to Neutral from Buy...
JP Morgan upgrading EPNY to Neutral from Underweight and downgrading EW to Underweight from Neutral...
RBC cuts UNFI to Sector Perform from Outperform...
Wachovia upgrading VZ to Mkt Perform from Underperform...
Smith Barney raising HAS to Buy from Hold...
BofA Sec downgrading SUN to Neutral from Buy...
Prudential initiating coverage on SWY, KR with Overweight and ABS, WIN with Underweight...
SunTrust downgrading RARE to EqualWeight from Overweight...
Deutsche Bank calling weakness in NKTR unfounded; firm also upgrading THQI to Hold from Sell.
Gruß
MadX
besonders Amgen und Medi dreuen mich